vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at Rodman & Renshaw

Stock analysts at Rodman & Renshaw assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued on Tuesday. The firm set a “buy” rating and a $67.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s target price indicates a potential upside of 84.73% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on VTVT. BTIG Research reissued a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Zacks Research cut shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Evercore started coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and an average price target of $55.33.

vTv Therapeutics Trading Up 3.4%

Shares of NASDAQ VTVT opened at $36.27 on Tuesday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The stock has a 50 day moving average of $33.92 and a 200-day moving average of $35.66. The company has a market capitalization of $142.90 million, a P/E ratio of -39.00 and a beta of 0.27.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $1.44. The company had revenue of $36.84 million for the quarter, compared to the consensus estimate of $20.00 million. Analysts predict that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the fourth quarter valued at about $221,000. Geode Capital Management LLC grew its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the last quarter. 683 Capital Management LLC bought a new position in vTv Therapeutics during the 4th quarter worth $731,000. Finally, Baker BROS. Advisors LP grew its position in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.